E-pharmacology 4 PDF
Document Details
Uploaded by CharitableCerberus1189
The University of Nottingham
Tags
Summary
This document discusses various targeted therapies for cancer, including VEGF inhibitors, Receptor Tyrosine Kinase Inhibitors (RTKIs), and anti-HER2 therapies. It examines mechanisms of action, side effects, and clinical outcomes for different treatments. Information is presented in the form of diagrams, tables, and text.
Full Transcript
process of normal angiogenesis MeCh of VEGF inhibition ① Monoclonal-antibody inhibition of VEGFA : Bevacizumab Inhibition of VEGFR2 : Sorafenib vs Axitinib Incidence2 Severity of hypertension...
process of normal angiogenesis MeCh of VEGF inhibition ① Monoclonal-antibody inhibition of VEGFA : Bevacizumab Inhibition of VEGFR2 : Sorafenib vs Axitinib Incidence2 Severity of hypertension after treatment with anti-vict therapies Drug Patient Any ³ Grade Any HT s (N) HTN 3 HTN in with with controls? drug drug Sunitinib 735 24 % 8% 1% Sorafenib 902 17 % 4% 2% Bevacizuma 649 26 % 3% 9% consequences of VEGF b inhibition Pazopanib 435 40 % 4% 10 % Vandetanib 106 21 % 2% 9% How do anti-VEGF therapies work ? to no need know cardiovascular effects of anti-VEGF therapies Resistance to targeted VEGF therapy # Targeting Growth Signalling : HER2 Monoclonal antibodies : inhibition of HER2 (trastuzumab) Hormones : inhibition of Estrogen Receptor Immunotherapy/Vaccines : HPV vacare Immunotherapies : Re-programming immune System cell CAR-T therapy Immunotherapy effector Mechanism
